Company: BDRX
Filing Date: 2025-04-29
Form Type: POS AM
Source: 0001214659-25-006581
Chunk: 50

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-04-29
Form: POS AM
Chunk 50
---
under are transferable, in whole or in part, upon surrender of the warrant, together with a written assignment
of the warrant subject to applicable securities laws; provided, however, that the Warrant Agent Warrants are subject to certain FINRA
transfer restrictions. We do not intend to apply for listing of the warrants on any securities exchange or other trading system.

No Rights as Shareholder Until Exercise.Except as set forth in the warrants, the holders of the warrants do not have any voting rights, dividends or other rights as a holder of our capital stock until they exercise the warrants.

Series J Warrants, Series K Warrants and July 2024 Placement Agent Warrants

The following is a brief summary of the Series J Warrants, Series K Warrants, and July 2024 Placement Agent Warrants, issued in connection with a July 2024 private placement, and is subject in all respects to the provisions contained in the applicable warrants,which
are filed as exhibits to our Report on Form 6-K dated July 19, 2024. Unless otherwise stated, references to “warrants” in this subsection include the Series J Warrants, Series K Warrants and July 2024 Placement Agent Warrants.

Exercisability.
The warrants became exercisable on July 22, 2024. The Series J Warrants, Series K Warrants and July 2024 Placement Agent Warrants expire five years, five years and three years, respectively from the initial exercise date.
The holder shall deliver the aggregate exercise price for the Depositary Shares specified in the exercise notice within two trading days
following the date of exercise (subject to the ‘cashless exercise’ arrangements described below).

Cashless Exercise. If, following the date that is six months from the initial issuance date of the warrant, a registration statement registering
the issuance of the securities underlying the warrants under the Securities Act is not then effective, or the prospectus contained therein
is not available for the resale of the securities issuable upon exercise of the applicable warrants, then in lieu of making the cash payment
otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise price, the holder may elect instead to
receive upon such exercise (either in whole or in part) the net number of Depositary Shares determined according to a formula set forth
in the warrants.

| 31 |

Exercise Price.The exercise price of each Series J Warrant, Series K Warrant and July 2024 Placement Agent Warrant is $25.